Organon (OGN) Liabilities from Discontinued Operations (2020 - 2025)
Organon (OGN) recorded quarterly Liabilities from Discontinued Operations of 32000000.0 in Q4 2025, down 27.27% quarter-over-quarter from 44000000.0 in Q1 2021.
Organon (OGN) Liabilities from Discontinued Operations (2020 - 2025) Analysis & Trends
Organon's Liabilities from Discontinued Operations history runs 3 years deep, the most recent figure standing at 32000000.0 for Q4 2025.
- In Q4 2025, Liabilities from Discontinued Operations changed N/A year-over-year to 32000000.0; the TTM figure through Dec 2025 stood at 32000000.0 (changed N/A YoY), while the FY2025 annual figure was 32000000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations was 32000000.0 for Q4 2025 at Organon, down from 44000000.0 in the prior quarter.
- In the past five years, Liabilities from Discontinued Operations ranged from a high of 44000000.0 in Q1 2021 to a low of 32000000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn |
| 10 | Organon | 3.50 Bn | 2.39 Bn | 783.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 32.00 Mn |
| Dec 31, 2025 | 32.00 Mn |
| Mar 31, 2021 | 44.00 Mn |
| Mar 31, 2021 | 44.00 Mn |
| Dec 31, 2020 | 83.00 Mn |
| Dec 31, 2020 | 83.00 Mn |